JAK1 and psoriasis: IL‐17 was also not inhibited by JAK1 inhibition as opposed to the pan‐JAK inhibitors, perhaps questioning its efficacy in diseases such as psoriasis and ankylosing spondylitis where both pan‐JAK inhibitors and anti‐IL‐17 biologicals have shown great clinical efficacy.81